Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 molnupiravir studies
Outcomes in molnupiravir studies. There is substantial positive publication bias. Two trials (CTRI/2021/05/033864, and CTRI/2021/08/0354242) have reported no significant efficacy, however the results have not been published yet. Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 34% 8 3,015 Improvement, Studies, Patients Relative Risk Mortality 50% 3 1,901 Hospitalization 57% 2 943 Recovery 15% 5 906 Viral clearance 42% 3 639 RCTs 34% 8 3,015 RCT mortality 50% 3 1,901 Peer-reviewed 36% 4 2,458 Early 55% 5 2,724 Late -8% 3 291 Molnupiravir for COVID-19 c19mp.com Jan 21, 2022 Favors molnupiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tau​2 = 0.24, I​2 = 53.7%, p = 0.013 Early treatment 55% 0.45 [0.24-0.85] 54/1,407 129/1,317 55% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Tau​2 = 0.00, I​2 = 0.0%, p = 0.77 Late treatment -8% 1.08 [0.67-1.73] 11/216 1/75 -8% improvement All studies 34% 0.66 [0.38-1.13] 65/1,623 130/1,392 34% improvement 8 molnupiravir COVID-19 studies c19mp.com Jan 21, 2022 Tau​2 = 0.32, I​2 = 65.6%, p = 0.13 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Tau​2 = 0.00, I​2 = 0.0%, p = 0.024 Early treatment 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Late treatment -282% 3.82 [0.50-29.1] 11/216 1/75 -282% improvement All studies 50% 0.50 [0.05-5.45] 12/1,065 11/836 50% improvement 3 molnupiravir COVID-19 mortality results c19mp.com Jan 21, 2022 Tau​2 = 2.97, I​2 = 67.3%, p = 0.58 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Tau​2 = 0.34, I​2 = 31.6%, p = 0.19 Early treatment 57% 0.43 [0.13-1.49] 10/511 24/432 57% improvement All studies 57% 0.43 [0.13-1.49] 10/511 24/432 57% improvement 2 molnupiravir COVID-19 hospitalization results c19mp.com Jan 21, 2022 Tau​2 = 0.34, I​2 = 31.6%, p = 0.19 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0005 Early treatment 74% 0.26 [0.12-0.55] 8/1,220 33/1,131 74% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Late treatment -282% 3.82 [0.50-29.1] 11/216 1/75 -282% improvement All studies 58% 0.42 [0.11-1.66] 19/1,436 34/1,206 58% improvement 4 molnupiravir COVID-19 serious outcomes c19mp.com Jan 21, 2022 Tau​2 = 1.04, I​2 = 55.3%, p = 0.22 Effect extraction pre-specified Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Tau​2 = 0.13, I​2 = 54.4%, p = 0.53 Early treatment 18% 0.82 [0.44-1.52] 8/383 3/376 18% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.97 Late treatment 1% 0.99 [0.74-1.34] 0/72 0/75 1% improvement All studies 15% 0.85 [0.66-1.11] 8/455 3/451 15% improvement 5 molnupiravir COVID-19 recovery results c19mp.com Jan 21, 2022 Tau​2 = 0.03, I​2 = 35.2%, p = 0.24 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Improvement, RR [CI] Treatment Control Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Early treatment 57% 0.43 [0.32-0.58] 48/293 102/234 57% improvement Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Late treatment 12% 0.88 [0.62-1.25] 26/52 34/60 12% improvement All studies 42% 0.58 [0.33-1.02] 74/345 136/294 42% improvement 3 molnupiravir COVID-19 viral clearance results c19mp.com Jan 21, 2022 Tau​2 = 0.18, I​2 = 79.2%, p = 0.058 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tau​2 = 0.24, I​2 = 53.7%, p = 0.013 Early treatment 55% 0.45 [0.24-0.85] 54/1,407 129/1,317 55% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Tau​2 = 0.00, I​2 = 0.0%, p = 0.77 Late treatment -8% 1.08 [0.67-1.73] 11/216 1/75 -8% improvement All studies 34% 0.66 [0.38-1.13] 65/1,623 130/1,392 34% improvement 8 molnupiravir COVID-19 Randomized Controlled Trials c19mp.com Jan 21, 2022 Tau​2 = 0.32, I​2 = 65.6%, p = 0.13 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Tau​2 = 0.00, I​2 = 0.0%, p = 0.024 Early treatment 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Late treatment -282% 3.82 [0.50-29.1] 11/216 1/75 -282% improvement All studies 50% 0.50 [0.05-5.45] 12/1,065 11/836 50% improvement 3 molnupiravir COVID-19 RCT mortality results c19mp.com Jan 21, 2022 Tau​2 = 2.97, I​2 = 67.3%, p = 0.58 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tau​2 = 0.95, I​2 = 75.1%, p = 0.21 Early treatment 57% 0.43 [0.12-1.60] 16/1,092 35/1,075 57% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Late treatment -282% 3.82 [0.50-29.1] 11/216 1/75 -282% improvement All studies 36% 0.64 [0.18-2.24] 27/1,308 36/1,150 36% improvement 4 molnupiravir COVID-19 peer reviewed trials c19mp.com Jan 21, 2022 Tau​2 = 1.11, I​2 = 73.7%, p = 0.5 Effect extraction pre-specified Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Fischer (RCT) 65% 0.35 [0.01-8.33] death 0/55 1/62 Fischer (RCT) 67% 0.33 [0.01-8.03] death 0/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] death 0/23 1/62 Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Fischer (RCT) -13% 1.13 [0.07-17.6] hosp. 1/55 1/62 Fischer (RCT) -100% 2.00 [0.19-21.5] hosp. 2/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] hosp. 0/23 1/62 Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Fischer (RCT) 89% 0.11 [0.01-0.86] viral+ 1/53 9/54 Fischer (RCT) 30% 0.70 [0.25-1.93] viral+ 5/43 9/54 Fischer (RCT) -9% 1.09 [0.37-3.18] viral+ 4/22 9/54 Fischer (RCT) 92% 0.08 [0.01-0.62] viral+ 1/117 6/54 Fischer (RCT) 92% 0.08 [0.00-1.34] viral+ 0/53 6/54 Fischer (RCT) 91% 0.09 [0.00-1.48] viral+ 0/42 6/54 Fischer (RCT) 59% 0.41 [0.05-3.20] viral+ 1/22 6/54 Fischer (RCT) 30% 0.70 [0.37-1.36] viral+ 19/137 12/61 Fischer (RCT) 62% 0.38 [0.13-1.12] viral+ 4/53 12/61 Fischer (RCT) -8% 1.08 [0.54-2.18] viral+ 13/61 12/61 Fischer (RCT) 56% 0.44 [0.11-1.83] viral+ 2/23 12/61 Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Khoo (RCT) -100% 2.00 [0.28-14.2] no recov. 4/12 1/6 Khoo (RCT) -100% 2.00 [0.90-4.43] no recov. 4/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Khoo (RCT) -200% 3.00 [0.39-23.1] no recov. 2/4 1/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Jayk Bernal (RCT) 30% 0.70 [0.49-0.99] hosp./death 48/709 68/699 Jayk Bernal (RCT) 94% 0.06 [0.00-0.97] hosp./death 0/37 9/47 Jayk Bernal (RCT) 50% 0.50 [0.20-1.26] hosp./death 6/75 13/82 Jayk Bernal (RCT) 24% 0.76 [0.42-1.38] hosp./death 18/237 22/221 Jayk Bernal (RCT) 42% 0.58 [0.20-1.68] hosp./death 5/47 7/38 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Arribas (DB RCT) -217% 3.17 [0.34-29.8] death 3/71 1/75 Arribas (DB RCT) -317% 4.17 [0.48-36.4] death 4/72 1/75 Arribas (DB RCT) -311% 4.11 [0.47-35.9] death 4/73 1/75 Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) Arribas (DB RCT) 12% 0.88 [0.61-1.28] no recov. 73 (n) 75 (n) Arribas (DB RCT) -1% 1.01 [0.69-1.47] no recov. 73 (n) 75 (n) Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 Arribas (DB RCT) -2% 1.02 [0.74-1.41] viral+ 29/50 34/60 Arribas (DB RCT) 21% 0.79 [0.56-1.13] viral+ 27/60 34/60 Arribas (DB RCT) 8% 0.92 [0.41-2.08] viral+ 9/53 10/54 Arribas (DB RCT) -48% 1.48 [0.72-3.03] viral+ 14/51 10/54 Arribas (DB RCT) 21% 0.79 [0.34-1.84] viral+ 8/55 10/54 molnupiravir COVID-19 outcomes c19mp.com Jan 21, 2022 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit